SAS Output

18-JUN-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC STUDIES ONLY (TXCA=Y)

46% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1558 411 26% 887 -670 1067 -491
ERLYTX 76 292 384% 630 554 465 389
GI 476 68 14% 146 -329 206 -270
GU 450 126 28% 272 -177 307 -143
GYN 57 0 0% 0 -57 0 -57
LEUK 150 45 30% 97 -52 60 -90
LUNG 524 123 23% 265 -258 290 -234
LYMPH 172 12 7% 25 -146 16 -156
MELAN 55 46 84% 99 44 343 288
MMYEL 147 48 33% 103 -43 86 -61
OTHER 0 24   51 51 44 44
SXQOL 0 4   8 8 4 4
Total 3665 1199   2583 -1075 2888 -777

18-JUN-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES ONLY (TXCA=N)

46% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 1   2 2 1 1
BREAST 37 135 365% 291 254 165 128
CCD 0 744   1606 1606 1564 1564
GU 0 0   0 0 0 0
LEUK 69 7 10% 15 -53 8 -61
LUNG 43 323 751% 697 654 612 569
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 0   0 0 0 0
PREV 0 21   45 45 85 85
SURV 0 46   99 99 97 97
SXQOL 878 3 0% 6 -871 5 -873
Total 1172 1280   2761 1591 2537 1365

18-JUN-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS

46% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 1   2 2 1 1
BREAST 1595 546 34% 1179 -415 1232 -363
CCD 0 744   1606 1606 1564 1564
ERLYTX 76 292 384% 630 554 465 389
GI 476 68 14% 146 -329 206 -270
GU 450 126 28% 272 -177 307 -143
GYN 57 0 0% 0 -57 0 -57
LEUK 219 52 24% 112 -106 68 -151
LUNG 567 446 79% 963 396 902 335
LYMPH 225 12 5% 25 -199 16 -209
MELAN 55 46 84% 99 44 343 288
MMYEL 239 48 20% 103 -135 86 -153
OTHER 0 24   51 51 44 44
PREV 0 21   45 45 85 85
SURV 0 46   99 99 97 97
SXQOL 878 7 1% 15 -862 9 -869
Total 4837 2479   5347 517 5425 588

18-JUN-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)

46% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1012 259 26% 559 -452 578 -434
ERLYTX 76 187 246% 403 327 292 216
GI 418 46 11% 99 -318 134 -284
GU 375 89 24% 192 -182 219 -156
GYN 57 0 0% 0 -57 0 -57
LEUK 122 29 24% 62 -59 42 -80
LUNG 441 93 21% 200 -240 206 -235
LYMPH 129 11 9% 23 -105 15 -114
MELAN 55 30 55% 64 9 174 119
MMYEL 85 48 56% 103 18 86 1
OTHER 0 24   51 51 44 44
SXQOL 0 4   8 8 4 4
Total 2770 820   1764 -1000 1794 -976

18-JUN-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)

46% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 1   2 2 1 1
BREAST 10 135 1350% 291 281 165 155
CCD 0 538   1161 1161 1120 1120
GU 0 0   0 0 0 0
LEUK 69 7 10% 15 -53 8 -61
LUNG 30 209 697% 451 421 422 392
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 0   0 0 0 0
PREV 0 11   23 23 68 68
SURV 0 33   71 71 61 61
SXQOL 740 3 0% 6 -733 5 -735
Total 994 937   2020 1028 1850 856

18-JUN-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY

46% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 1   2 2 1 1
BREAST 1022 394 39% 850 -171 743 -279
CCD 0 538   1161 1161 1120 1120
ERLYTX 76 187 246% 403 327 292 216
GI 418 46 11% 99 -318 134 -284
GU 375 89 24% 192 -182 219 -156
GYN 57 0 0% 0 -57 0 -57
LEUK 191 36 19% 77 -113 50 -141
LUNG 471 302 64% 652 181 628 157
LYMPH 182 11 6% 23 -158 15 -167
MELAN 55 30 55% 64 9 174 119
MMYEL 177 48 27% 103 -73 86 -91
OTHER 0 24   51 51 44 44
PREV 0 11   23 23 68 68
SURV 0 33   71 71 61 61
SXQOL 740 7 1% 15 -724 9 -731
Total 3764 1757   3786 29 3644 -120

18-JUN-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES

46% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 65 360 554% 777 712 900 835
CCD 0 744   1606 1606 1564 1564
GI 81 20 25% 43 -37 37 -44
GU 215 79 37% 170 -44 150 -65
LEUK 0 7   15 15 8 8
LUNG 53 25 47% 53 0 79 26
LYMPH 7 5 71% 10 3 5 -2
MELAN 0 2   4 4 251 251
MMYEL 0 47   101 101 85 85
OTHER 0 0   0 0 6 6
PREV 0 21   45 45 85 85
SURV 0 46   99 99 97 97
SXQOL 878 7 1% 15 -862 9 -869
Total 1299 1363   2938 1642 3276 1977

18-JUN-2018 6:10

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

The REPORT Procedure

Detailed and/or summarized report

Table 1

Comm. Phase Study Stat
Center
Open
Date
Months
Open
Total
Regs
Accrual
Goal
Monthly
Accrual
Rate
Date of
Expected Closure or
Temporary Closure
    EAF151 ECOG-ACR     1      
BREAST II S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 SWOG 07JUL2016:00:00:00 23 244 333 9.0 Mar-2019
  II-III NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG 24DEC2014:00:00:00   1   0.0  
  III A011106 Breast, Neoadj, ALTERNATE study ALLIANCE 15FEB2014:00:00:00   59   1.3  
    A011202 Breast, Nodal XRT +/- ALND ALLIANCE     72      
    A011401 Breast, adj, Stage II/III HER2-, weight loss ALLIANCE 29AUG2016:00:00:00   147   9.2  
    A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo ALLIANCE 08DEC2016:00:00:00   46   4.0  
    B51 Breast, Regional Nodal XRT NRG     27      
    B55 Brst, Adj Olaparib for BRCA,TNBC NRG 03JUL2014:00:00:00   26   0.7  
    E2112 Brst,Adv,Exemestane+/-Entinostat ECOG-ACR 02JAN2014:00:00:00   50   1.2  
    EA1151 Brst, Tomosynthesis Mammographic Screening ECOG-ACRIN 06JUL2017:00:00:00   108   18.0  
    NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG 22JAN2015:00:00:00   56   1.3  
    S1207 Brst,Adj,Endocrine+/-Everolimus SWOG 03SEP2013:00:00:00 57 1625 1900 30.5 Mar-2019
    S1222 Brst,Fulv. +/- Ever. +/- Anastr. SWOG 09MAY2014:00:00:00   37 840   Feb-2015 Temp Close
    S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) SWOG 15NOV2016:00:00:00 19 208 1000 17.0 Apr-2022
  OTHER A221405 Breast, ET interruption, Pregnancy Outcomes ALLIANCE 15OCT2015:00:00:00   9   0.2  
    E1Z11 Brst,Genetic Predictors of AIMSS ECOG-ACRIN 10MAY2013:00:00:00   150   0.7  
CCD III A011104 Preoperative Breast MRI ALLIANCE 21FEB2014:00:00:00   14   0.3  
    A191402C PROS, Testing Decision Aids for Minority Men Alliance 14JUL2017:00:00:00   8   1.0  
    S1415CD TrACER CSF Standing Order Intervention for FN SWOG 01SEP2016:00:00:00 21 1864 3960 110.2 Jan-2020
  OTHER S1417CD Colorectal, Cost Cohort Study SWOG 13MAY2016:00:00:00 25 261 374 19.5 Nov-2018
ERLYTX II A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib ALLIANCE 06AUG2015:00:00:00   5   0.0  
    S1609 Rare Tumor, Comb Nivo/Ipi SWOG 13JAN2017:00:00:00 17 514 707 52.0 Sep-2018
  II-III A071102 GBM, adj TMZ +/- Veliparib ALLIANCE 19SEP2014:00:00:00   43   0.8  
    ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) COG 16MAY2014:00:00:00   9   0.8  
  OTHER EAY131 MATCH ECOG-ACR 12AUG2015:00:00:00   110   1.5  
GI II A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT ALLIANCE 01DEC2016:00:00:00   15   0.8  
    EA2142 GI NEC, Adv G3, EP vs TMZ + CAP ECOG-ACRIN 06NOV2015:00:00:00   4   0.0  
    NRGGI002 Rectal, Ph II, Sensitization using TNT NRG 12OCT2016:00:00:00   6   0.3  
    S1613 mCRC, Adv/Met, TP vs CETIRI SWOG 09OCT2017:00:00:00 8 6 130 1.0 Oct-2028
  II-III N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX ALLIANCE 13JAN2012:00:00:00   151   3.0  
  III A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC ALLIANCE 12SEP2017:00:00:00   4   0.7  
    NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy NRG 07NOV2017:00:00:00   1   0.2  
    R0848 Panc, Adj, Erlotinib v ChemoRT NRG 01MAR2014:00:00:00   20   0.0  
GU II S1500 pRCC,Adv, Sunitinib vs MET inhib SWOG 05APR2016:00:00:00 26 87 180 4.3 Mar-2020
    S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab SWOG 07FEB2017:00:00:00 16 51 148 4.3 Apr-2020
  II-III NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel NRG 30DEC2016:00:00:00   1   0.0  
  III A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) ALLIANCE 01JUL2015:00:00:00   3   0.2  
    A031501 Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs ALLIANCE 21SEP2017:00:00:00   1   0.2  
    EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) ECOG-ACR 02FEB2017:00:00:00   12   1.2  
    R0924 Pros, NADT+WPRT vs. NADT+P&SV RT NRG 07JUL2011:00:00:00   79   3.2  
    S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG SWOG 07FEB2017:00:00:00 16 111 969 9.0 May-2026
LEUK I S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP SWOG 01APR2014:00:00:00 50 38 38 0.2 Jun-2018
  I-II S1318 ALL, Age 65+, Ph±, Blinatumomab SWOG 12JAN2015:00:00:00   47 44   Sep-2017 Temp Close
  II-III S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics SWOG 22DEC2017:00:00:00 5 29 1670 4.9 > 15 Yrs
  III E1910 BCR-ABL-neg, B ALL, Blinatumomab ECOG-ACRIN 23DEC2013:00:00:00   86   2.7  
    E2906 AML, Age 60+, Clo vs Dauno+Cy ECOG-ACRIN 24FEB2011:00:00:00   75   0.0  
  OTHER NHLBIMDS LEUK, National MDS Study ECOG-ACRIN 05APR2016:00:00:00   12   1.2  
LUNG II S1400F Non-Match: MEDI4736 + Tremelimumab SWOG 02OCT2017:00:00:00 8 21 132 2.8 Sep-2021
    S1400G HRRD: Talazoparib (BMN 673) SWOG 07FEB2017:00:00:00 16 48 60 2.5 Oct-2018
    S1400K c-Met: ABBV-399 (Process II) SWOG 05FEB2018:00:00:00 4 15 44 3.4 Feb-2019
  II-III NRGCC003 SCLC, PCI or HA-PCI NRG 07DEC2015:00:00:00   4   0.0  
  III A081105 ALCHEMIST1, EGFR mut, Erlotinib ALLIANCE 02JAN2014:00:00:00   39   1.3  
    C30610 SCLC, Thoracic RT ALLIANCE 21MAR2008:00:00:00   56   0.2  
    E4512 ALCHEMIST2, ALK mut, Crizotinib ECOG-ACR 18AUG2014:00:00:00   8   0.2  
    EA5142 ALCHEMIST3, Non-match, Nivolumab ECOG-ACRIN 16MAY2016:00:00:00   49   3.2  
  OTHER A151216 ALCHEMIST0 - screening ALLIANCE 06FEB2014:00:00:00   525   18.8  
    S1400 SCCA,Adv, Biomarker Master SWOG 15JUN2014:00:00:00 48 1682   38.3  
  PILOT S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC SWOG 03NOV2017:00:00:00 7 0 28 0.0 Dec-2031
LYMPH II S1608 Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob SWOG 10AUG2017:00:00:00 10 6 150 1.0 Jun-2030
  III A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo ALLIANCE 15JUL2016:00:00:00   6   0.2  
    EA4151 Lymph, AHCT +/-Ritux, MRD Neg ECOG-ACRIN 29AUG2017:00:00:00   5   0.8  
MELAN II S1320 Adv, BRAF mut, Inter v Contin SWOG 22JUL2014:00:00:00 46 218 280 4.8 Jun-2019
    S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) SWOG 20OCT2016:00:00:00 19 11 77 1.2 Feb-2023
    S1607 MELAN, Adv, T-VEC, MK-3475 SWOG 02OCT2017:00:00:00 8 1 64 0.2 > 15 Yrs
    S1616 MELAN, Adv, Ipilimumab ± Nivolumab SWOG 17JUL2017:00:00:00 11 14 94 1.8 Jan-2022
  II-III EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim ECOG-ACRIN 01MAR2016:00:00:00   36   0.0  
  III EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T ECOG-ACR 15DEC2015:00:00:00   26   0.3  
MMYEL II S1702 AL Amyloidosis, Relapsed, Isatuximab SWOG 08MAR2018:00:00:00 3 1 39 0.3 Dec-2028
  III E1A11 MM, frontline, BLD vs CLD ECOG-ACRIN 22NOV2013:00:00:00   205   8.2  
OTHER I-II A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II ALLIANCE 26JAN2015:00:00:00   19   2.2  
  II A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo ALLIANCE 02SEP2014:00:00:00   2   0.0  
    A091305 HN, Adv, Thyroid PPAR agonist + Chemo ALLIANCE 01SEP2014:00:00:00   2   0.0  
    A091401 Sarc, ALLIANCE 18JUN2015:00:00:00   9   0.5  
    A091404 HN, AR+, Enzalutamide ALLIANCE 25SEP2015:00:00:00   8   0.0  
    EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp ECOG-ACRIN 29MAR2016:00:00:00   8   0.7  
    NRGBN001 HN, novel vs. std chemoradiation + chemo NRG 28AUG2015:00:00:00   1   0.0  
  II-III G0281 Ovar, Recur/prog LG, IC chemo vs trametinib NRG 27FEB2014:00:00:00   1   0.0  
    G0286B Adv Endometrial,Metformin/Chemo NRG     1      
    NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG 06FEB2016:00:00:00   3   0.0  
    NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG 21APR2014:00:00:00   4   0.0  
    R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux NRG 18MAR2013:00:00:00   3   0.0  
  III G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT NRG 12APR2010:00:00:00   1   0.0  
    N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC ALLIANCE     7      
    NRGGY011 ENDO, SURG WINDOW, MPA VS MPA+ENTINOSTAT NRG 12APR2010:00:00:00   2   0.2  
    R0724 Cervical, Chem+RT +/- Adj. Chemo NRG 15JAN2014:00:00:00   1   0.0  
    R0920 HN, Adv, Postop IMRT ± Cetuximab NRG 24DEC2013:00:00:00   11   0.0  
  OTHER EAQ152 Communication & education in tumor profiling ECOG-ACR 26SEP2016:00:00:00   11   0.0  
PREV III A211102 Breast, Atypia via RPFNA, Metformin v Placebo ALLIANCE 01FEB2015:00:00:00   3   0.0  
    S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac SWOG 01MAR2013:00:00:00 63 197 480 4.2 Jan-2024
SURV III E1Q11 EROS: Reproductive Health in Cancer Survivors ECOG-ACR 30SEP2015:00:00:00   11   0.7  
    S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol SWOG 15SEP2017:00:00:00 9 14 817 1.8 > 15 Yrs
  OTHER EA9131 Leuk, Strategy to decrease early APL deaths ECOG-ACR 16AUG2017:00:00:00   8   1.0  
    S1316 Compar. Effectiv. Trial for MBO SWOG 02JUN2018:00:00:00 0 155 200 0.0 > 15 Yrs
SXQOL III A221101 Glioma, Nuvigil/Placebo Fatigue ALLIANCE 03JUN2013:00:00:00   20   0.5  
    NRGGU003 Pros, Post-Prostatectomy HYPORT vs COPORT NRG 28JUL2017:00:00:00   4   0.7  
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

18-JUN-2018 6:10

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

The REPORT Procedure

Detailed and/or summarized report

Table 1

Phase Comm. Int
grp
Stat
Center
Study NCIPROTO CA
Cntrl
Study
Temp
Close
OTHER BREAST Y ECOG-ACRIN E1Z11 Brst,Genetic Predictors of AIMSS E1Z11 Y  
    Y ALLIANCE A221405 Breast, ET interruption, Pregnancy Outcomes A221405 Y  
  CCD N   S1417CD Colorectal, Cost Cohort Study   Y  
  ERLYTX Y ECOG-ACR EAY131 MATCH EAY131 N  
  LEUK Y ECOG-ACRIN NHLBIMDS LEUK, National MDS Study NHLBI-MDS Y  
  LUNG Y SWOG S1400 SCCA,Adv, Biomarker Master S1400 N  
    Y ALLIANCE A151216 ALCHEMIST0 - screening A151216 N  
  OTHER Y ECOG-ACR EAQ152 Communication & education in tumor profiling EAQ152 Y  
  SURV Y SWOG S1316 Compar. Effectiv. Trial for MBO S1316 Y  
    Y ECOG-ACR EA9131 Leuk, Strategy to decrease early APL deaths EA9131 Y  
I LEUK N   S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP   N  
I-II LEUK Y SWOG S1318 ALL, Age 65+, Ph±, Blinatumomab S1318 N Y
  OTHER Y ALLIANCE A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II A091304 N  
II BREAST Y SWOG S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 S1416 N  
  ERLYTX Y SWOG S1609 Rare Tumor, Comb Nivo/Ipi S1609 N  
    Y ALLIANCE A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib A071401 N  
  GI Y SWOG S1613 mCRC, Adv/Met, TP vs CETIRI S1613 N  
    Y ECOG-ACRIN EA2142 GI NEC, Adv G3, EP vs TMZ + CAP EA2142 N  
    Y NRG NRGGI002 Rectal, Ph II, Sensitization using TNT NRG-GI002 N  
    Y ALLIANCE A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT A021501 N  
  GU Y SWOG S1500 pRCC,Adv, Sunitinib vs MET inhib S1500 N  
    Y SWOG S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab S1605 N  
  LUNG Y SWOG S1400G HRRD: Talazoparib (BMN 673) S1400G N  
    Y SWOG S1400K c-Met: ABBV-399 (Process II) S1400K N  
    Y SWOG S1400F Non-Match: MEDI4736 + Tremelimumab S1400F N  
  LYMPH Y SWOG S1608 Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob S1608 N  
  MELAN Y SWOG S1320 Adv, BRAF mut, Inter v Contin S1320 N  
    Y SWOG S1607 MELAN, Adv, T-VEC, MK-3475 S1607 N  
    Y SWOG S1616 MELAN, Adv, Ipilimumab ± Nivolumab S1616 N  
    Y SWOG S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) S1512 N  
  MMYEL Y SWOG S1702 AL Amyloidosis, Relapsed, Isatuximab S1702 N  
  OTHER Y NRG NRGBN001 HN, novel vs. std chemoradiation + chemo NRG-BN001 N  
    Y ALLIANCE A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo A091202 N  
    Y ALLIANCE A091401 Sarc, A091401 N  
    Y ALLIANCE A091305 HN, Adv, Thyroid PPAR agonist + Chemo A091305 N  
    Y ALLIANCE A091404 HN, AR+, Enzalutamide A091404 N  
    Y ECOG-ACRIN EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp EA3132 N  
PILOT LUNG Y SWOG S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC S1619 N  
II-III BREAST Y NRG NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG-BR002 N  
  ERLYTX Y ALLIANCE A071102 GBM, adj TMZ +/- Veliparib A071102 N  
    Y COG ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) ARST1321 N  
  GI Y ALLIANCE N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX N1048 Y  
  GU Y NRG NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel NRG-GU002 N  
  LEUK Y SWOG S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics S1612 N  
  LUNG Y NRG NRGCC003 SCLC, PCI or HA-PCI NRG-CC003 Y  
  MELAN Y ECOG-ACRIN EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim EA6141 N  
  OTHER Y NRG NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG-GY005 Y  
    Y NRG G0286B Adv Endometrial,Metformin/Chemo GOG-0286B Y  
    Y NRG R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux RTOG-1216 Y  
    Y NRG NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG-HN001 Y  
    Y NRG G0281 Ovar, Recur/prog LG, IC chemo vs trametinib GOG-0281 Y  
III BREAST N   S1222 Brst,Fulv. +/- Ever. +/- Anastr.   N Y
    Y SWOG S1207 Brst,Adj,Endocrine+/-Everolimus S1207 Y  
    Y SWOG S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) S1418 Y  
    Y ALLIANCE A011202 Breast, Nodal XRT +/- ALND A011202    
    Y ALLIANCE A011106 Breast, Neoadj, ALTERNATE study A011106 N  
    Y NRG B51 Breast, Regional Nodal XRT NSABP-B-51 Y  
    Y ALLIANCE A011401 Breast, adj, Stage II/III HER2-, weight loss A011401 Y  
    Y NRG NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG-BR003 N  
    Y ECOG-ACR E2112 Brst,Adv,Exemestane+/-Entinostat E2112 Y  
    Y ALLIANCE A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo A011502 Y  
    Y ECOG-ACRIN EA1151 Brst, Tomosynthesis Mammographic Screening EA1151 N  
    Y NRG B55 Brst, Adj Olaparib for BRCA,TNBC NSABP-B-55 Y  
  CCD Y SWOG S1415CD TrACER CSF Standing Order Intervention for FN S1415CD Y  
    Y ALLIANCE A011104 Preoperative Breast MRI A011104 Y  
    Y Alliance A191402C PROS, Testing Decision Aids for Minority Men A191402CD Y  
  GI Y NRG R0848 Panc, Adj, Erlotinib v ChemoRT RTOG-0848 Y  
    Y ALLIANCE A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC A021502 Y  
    Y NRG NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy NRG-GI004 Y  
  GU Y SWOG S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG S1602 Y  
    Y NRG R0924 Pros, NADT+WPRT vs. NADT+P&SV RT RTOG-0924 Y  
    Y ECOG-ACR EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) EA8143 Y  
    Y ALLIANCE A031501 Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs A031501 Y  
    Y ALLIANCE A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) A031102 Y  
  LEUK Y ECOG-ACRIN E2906 AML, Age 60+, Clo vs Dauno+Cy E2906 Y  
    Y ECOG-ACRIN E1910 BCR-ABL-neg, B ALL, Blinatumomab E1910 N  
  LUNG Y ALLIANCE C30610 SCLC, Thoracic RT CALGB-30610 Y  
    Y ALLIANCE A081105 ALCHEMIST1, EGFR mut, Erlotinib A081105 N  
    Y ECOG-ACRIN EA5142 ALCHEMIST3, Non-match, Nivolumab EA5142 N  
    Y ECOG-ACR E4512 ALCHEMIST2, ALK mut, Crizotinib E4512 N  
  LYMPH Y ECOG-ACRIN EA4151 Lymph, AHCT +/-Ritux, MRD Neg EA4151 Y  
    Y ALLIANCE A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo A051301 N  
  MELAN Y ECOG-ACR EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T EA6134 Y  
  MMYEL Y ECOG-ACRIN E1A11 MM, frontline, BLD vs CLD E1A11 Y  
  OTHER Y NRG R0920 HN, Adv, Postop IMRT ± Cetuximab RTOG-0920 Y  
    Y ALLIANCE N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC N0577 N  
    Y NRG G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT GOG-0263 Y  
    Y NRG NRGGY011 ENDO, SURG WINDOW, MPA VS MPA+ENTINOSTAT NRG-GY011 N  
    Y NRG R0724 Cervical, Chem+RT +/- Adj. Chemo RTOG-0724 Y  
  PREV Y SWOG S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac S0820 Y  
    Y ALLIANCE A211102 Breast, Atypia via RPFNA, Metformin v Placebo A211102 Y  
  SURV Y SWOG S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol S1501 Y  
    Y ECOG-ACR E1Q11 EROS: Reproductive Health in Cancer Survivors E1Q11 Y  
  SXQOL Y ALLIANCE A221101 Glioma, Nuvigil/Placebo Fatigue A221101 Y  
    Y NRG NRGGU003 Pros, Post-Prostatectomy HYPORT vs COPORT NRG-GU003 Y  
    Y ECOG-ACR EAF151 EAF151